<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="is permitted which does not comply with these terms. Abstract" exact="Severe" post="acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the third"/>
 <result pre="permitted which does not comply with these terms. Abstract Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) is the third coronavirus"/>
 <result pre="which does not comply with these terms. Abstract Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) is the third coronavirus leading"/>
 <result pre="does not comply with these terms. Abstract Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) is the third coronavirus leading to"/>
 <result pre="outbreak. Despite the high mortality rates from SARS-CoV-1 and Middle-East" exact="respiratory" post="syndrome (MERS)-CoV infections, which both sparked the interest of"/>
 <result pre="Despite the high mortality rates from SARS-CoV-1 and Middle-East respiratory" exact="syndrome" post="(MERS)-CoV infections, which both sparked the interest of the"/>
 <result pre="In this work, we focus on the association between obesity," exact="metabolic syndrome," post="and type 2 diabetes on the one hand, and"/>
 <result pre="we focus on the association between obesity, metabolic syndrome, and" exact="type 2" post="diabetes on the one hand, and the severity of"/>
 <result pre="on the association between obesity, metabolic syndrome, and type 2" exact="diabetes" post="on the one hand, and the severity of COVID-19"/>
 <result pre="diabetes on the one hand, and the severity of COVID-19" exact="infection" post="on the other, as it seems greater in these"/>
 <result pre="to a specific immune environment that predisposes obese patients to" exact="respiratory" post="failure during COVID-19. We also hypothesize that an ACE2-cleaved"/>
 <result pre="immune deregulation and that its low expression during the SARS-CoV-2" exact="infection" post="could explain the severity of infection. This introduces angiotensin"/>
 <result pre="interest in therapeutic research on CoV infections. coronavirus SARS-CoV ACE2" exact="obesity" post="adipocyte metabolic syndrome inflammation fig-count: table-count: equation-count: ref-count: page-count:"/>
 <result pre="therapeutic research on CoV infections. coronavirus SARS-CoV ACE2 obesity adipocyte" exact="metabolic syndrome" post="inflammation fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction Coronavirus"/>
 <result pre="research on CoV infections. coronavirus SARS-CoV ACE2 obesity adipocyte metabolic" exact="syndrome" post="inflammation fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction Coronavirus"/>
 <result pre="public health in general. The first outbreak caused by severe" exact="acute" post="respiratory syndrome coronavirus 1 (SARS-CoV-1) occurred between November 2002"/>
 <result pre="health in general. The first outbreak caused by severe acute" exact="respiratory" post="syndrome coronavirus 1 (SARS-CoV-1) occurred between November 2002 and"/>
 <result pre="in general. The first outbreak caused by severe acute respiratory" exact="syndrome" post="coronavirus 1 (SARS-CoV-1) occurred between November 2002 and July"/>
 <result pre="and then spreading worldwide (2). Although the symptoms of SARS-CoV-1" exact="infection" post="were in most cases non-specific, including lethargy, myalgia, and"/>
 <result pre="rate of 10% in case series was mostly related to" exact="respiratory" post="failure due to acute respiratory distress syndrome (ARDS) (3,"/>
 <result pre="case series was mostly related to respiratory failure due to" exact="acute" post="respiratory distress syndrome (ARDS) (3, 4). The physiopathology underlying"/>
 <result pre="series was mostly related to respiratory failure due to acute" exact="respiratory" post="distress syndrome (ARDS) (3, 4). The physiopathology underlying the"/>
 <result pre="mostly related to respiratory failure due to acute respiratory distress" exact="syndrome" post="(ARDS) (3, 4). The physiopathology underlying the severity of"/>
 <result pre="(ARDS) (3, 4). The physiopathology underlying the severity of SARS-CoV-1" exact="infection" post="remained unclear after the epidemic due to insufficient sampling."/>
 <result pre="A second CoV epidemic occurred in 2012 with Middle East" exact="respiratory" post="syndrome (MERS)-CoV, which has mostly led to small-size outbreaks"/>
 <result pre="second CoV epidemic occurred in 2012 with Middle East respiratory" exact="syndrome" post="(MERS)-CoV, which has mostly led to small-size outbreaks in"/>
 <result pre="in case series (case fatality rate of ~30%), mostly from" exact="respiratory" post="failure, which has led to the identification of unique"/>
 <result pre="has led to the identification of unique strategies of CoV" exact="infections" post="to escape the immune response. Due to the ending"/>
 <result pre="to the ending of the SARS-CoV-1 epidemic and the somewhat" exact="limited" post="number of cases of MERS-CoV in the recent years,"/>
 <result pre="MERS-CoV in the recent years, understanding the mechanisms of CoV" exact="infections" post="in humans has proven to be complex, and the"/>
 <result pre="remain difficult to extrapolate. In November 2019, cases of a" exact="pneumonia" post="with atypical features were reported in Wuhan, China; in"/>
 <result pre="to extrapolate. In November 2019, cases of a pneumonia with" exact="atypical" post="features were reported in Wuhan, China; in January 2020,"/>
 <result pre="SARS-CoV-2 was identified as the cause of this new CoV-induced" exact="disease" post="(COVID-19), which became a worldwide pandemic in the following"/>
 <result pre="being debated, ranging between 0.3 and 1.5%, it is still" exact="lower" post="than those associated with SARS-CoV-1 and MERS-CoV infections. Patients"/>
 <result pre="with SARS-CoV-1 and MERS-CoV infections. Patients suffering from severe SARS-CoV-2" exact="infection" post="could be healthy or only have mild comorbidities such"/>
 <result pre="could be healthy or only have mild comorbidities such as" exact="hypertension" post="or diabetes (8). Most of all, severe cases due"/>
 <result pre="healthy or only have mild comorbidities such as hypertension or" exact="diabetes" post="(8). Most of all, severe cases due to respiratory"/>
 <result pre="or diabetes (8). Most of all, severe cases due to" exact="respiratory" post="failure occur 7â€&quot;12 days after the first symptoms (9)."/>
 <result pre="to explore what underlies the link between immune response and" exact="respiratory" post="failure in CoV infections on the one hand, and"/>
 <result pre="the link between immune response and respiratory failure in CoV" exact="infections" post="on the one hand, and the current observation of"/>
 <result pre="infections on the one hand, and the current observation of" exact="obesity" post="as a risk factor for severe outcome in COVID-19"/>
 <result pre="for severe outcome in COVID-19 on the other. Physiopathology of" exact="Respiratory" post="Failure in Covid-19 Most of the time, the need"/>
 <result pre="severe outcome in COVID-19 on the other. Physiopathology of Respiratory" exact="Failure" post="in Covid-19 Most of the time, the need for"/>
 <result pre="the time, the need for intensive care during COVID-19 is" exact="secondary" post="to the onset of ARDS (9), as defined by"/>
 <result pre="published series, 30% of these ARDS cases were accompanied by" exact="septic shock" post="or other organ dysfunction (8, 10). The nature of"/>
 <result pre="by Calfee et al. (11). SARS-CoV-1-induced ARDS was associated with" exact="vascular" post="leakage and neutrophilic alveolitis (12), both of which are"/>
 <result pre="(11). SARS-CoV-1-induced ARDS was associated with vascular leakage and neutrophilic" exact="alveolitis" post="(12), both of which are compatible with a hyper-inflammatory"/>
 <result pre="observed ventilatory abnormalities suggestive of microcirculatory involvement such as hypoxic" exact="pulmonary" post="vasoconstriction or distal thrombosis (13, 14). This points to"/>
 <result pre="of microcirculatory involvement such as hypoxic pulmonary vasoconstriction or distal" exact="thrombosis" post="(13, 14). This points to the contribution of several"/>
 <result pre="14). This points to the contribution of several factors in" exact="respiratory" post="failure, with experts also citing the possible involvement of"/>
 <result pre="failure, with experts also citing the possible involvement of genuine" exact="viral pneumonia" post="as well as capillary thrombosis by neutrophil extracellular traps"/>
 <result pre="with experts also citing the possible involvement of genuine viral" exact="pneumonia" post="as well as capillary thrombosis by neutrophil extracellular traps"/>
 <result pre="possible involvement of genuine viral pneumonia as well as capillary" exact="thrombosis" post="by neutrophil extracellular traps (NETs) (15). The reason for"/>
 <result pre="by neutrophil extracellular traps (NETs) (15). The reason for this" exact="respiratory" post="outcome is most likely a complex interplay of multiple"/>
 <result pre="factors, which derive directly from CoV virulence. Role of the" exact="Viral" post="Gateway The membrane protein angiotensin-converting enzyme 2 (ACE2) is"/>
 <result pre="(20). In the lungs, it is expressed by 2% of" exact="epithelial" post="cells, increasing with cell differentiation, and it is mainly"/>
 <result pre="(Ang2) into Ang1-7. Ang2 binds to a receptor, the angiotensin" exact="type 1" post="receptor (AT1R), a transmembrane G protein-coupled receptor, which is"/>
 <result pre="found in a large variety of cells, ranging from smooth" exact="muscle" post="cells, endometrium, and myocardium to blood cells, renal interstitial,"/>
 <result pre="The activation of AT1R has several effects: for example, vasoconstriction," exact="vascular" post="permeability, macrophage maturation, and pro-inflammatory cytokine release. During the"/>
 <result pre="release. During the resolution phase of the inflammation, Ang2 promotes" exact="tumor" post="growth factor beta production and fibroblast proliferation, leading to"/>
 <result pre="ubiquitous G-protein-coupled receptor, implicated, among others, in retina development (22)," exact="muscle" post="wasting (23), and benign prostate hyperplasia (24). Activation of"/>
 <result pre="among others, in retina development (22), muscle wasting (23), and" exact="benign" post="prostate hyperplasia (24). Activation of the MAS receptor by"/>
 <result pre="in retina development (22), muscle wasting (23), and benign prostate" exact="hyperplasia" post="(24). Activation of the MAS receptor by Ang1-7 induces"/>
 <result pre="(25, 26) and reduces oxidative stress induced by Ang2 in" exact="vascular" post="injuries (27). In macrophages, it promotes an anti-inflammatory profile"/>
 <result pre="for example, by lowering pro-inflammatory cytokine production, notably IL-6 and" exact="tumor" post="necrosis factor alpha (TNFÎ±). Ang1-7 has also shown beneficial"/>
 <result pre="in inflammation resolution and fibrosis, notably in kidney and myocardial" exact="disease" post="(21, 29). The binding of ACE2 by SARS-CoV-2 prevents"/>
 <result pre="tampering was suggested to be an important mechanism in SARS-CoV-1" exact="infection" post="(30, 31). It was only later discovered that CoV"/>
 <result pre="immunity (32). These mechanisms, in addition to the pro-inflammatory response" exact="secondary" post="to ACE2 binding, might act as a trigger for"/>
 <result pre="binding, might act as a trigger for a sustained and" exact="uncontrolled" post="inflammatory response, leading to ARDS. Immune Polarization and Its"/>
 <result pre="leading to ARDS. Immune Polarization and Its Consequences During CoV" exact="Infections" post="In general, an efficient antiviral response is driven by"/>
 <result pre="as well as the release of specific cytokines, such as" exact="type 1" post="interferon (INF-1) by innate immune cells. INF-1 is produced"/>
 <result pre="by infected cells and innate immune cells after recognizing the" exact="viral" post="pathogen-associated molecular patterns (PAMPS), such as single-strained or uncapped"/>
 <result pre="deficient in either TLR3 or TRIF are more susceptible to" exact="viral" post="injuries and thus more at risk of developing ARDS"/>
 <result pre="and thus more at risk of developing ARDS during CoV" exact="infections" post="(33). INF-1 activates the Janus kinase-signal transducers and activators"/>
 <result pre="notably in the synthesis of specific cytokines, preferably oriented toward" exact="viral" post="control and clearance (34). Most of these steps, involved"/>
 <result pre="constitutive INF-1 production in bats (principal reservoir of CoV). CoV" exact="infections" post="are expert evaders of this antiviral response (35). Their"/>
 <result pre="escape plan revolves around three main mechanisms: - First, hiding" exact="viral" post="RNA from cytoplasmic PRR. After entering the cell, SARS-CoV-1"/>
 <result pre="from the cytosol (36, 37). The modified capping of the" exact="viral" post="RNA 2â€²-O-methylation also prevents the binding to an important"/>
 <result pre="viral RNA 2â€²-O-methylation also prevents the binding to an important" exact="cytosolic" post="PRR (38). - Next, direct tampering of the PRR-related"/>
 <result pre="selectively degrade host RNA via endonucleolytic activity against which the" exact="viral" post="RNA is protected (42, 43). The many mechanisms used"/>
 <result pre="of developing an efficient antiviral response. On the one hand," exact="viral" post="PAMPS do not result in INF-1 production. On the"/>
 <result pre="a specific cytokine profile, associating innate immunity chemokines (such as" exact="monocyte" post="chemoattractant protein 3 and interferon gamma-induced protein 10 (IP-10),"/>
 <result pre="protein 10 (IP-10), which are suggestive of macrophage activation and" exact="epithelial" post="suffering), and pro-inflammatory macrophage-produced cytokines such as IL-6 (45)."/>
 <result pre="and pro-inflammatory macrophage-produced cytokines such as IL-6 (45). Moreover, CoV" exact="infections" post="can directly induce the activation of nuclear factor kappa"/>
 <result pre="efficient antiviral response. High plasma levels of IL-6 and the" exact="absence of" post="INF-1 have been noted in severe patients (47), illustrating"/>
 <result pre="(47), illustrating a sustained innate response that fails to achieve" exact="viral" post="clearance and triggers ARDS. However, this sustained inflammation without"/>
 <result pre="microorganisms such as fungi and bacteria, but poorly effective against" exact="viral" post="pathogens (49). In general, viral PAMPS do not usually"/>
 <result pre="bacteria, but poorly effective against viral pathogens (49). In general," exact="viral" post="PAMPS do not usually polarize the immune response to"/>
 <result pre="association of severe outcome and inappropriate cytokine environment in CoV" exact="infection" post="suggests a link with immune polarization, as a result"/>
 <result pre="strategies. The resulting inefficient immune profile leads to a sustained" exact="viral" post="exposure and persistent inflammatory state. In addition to the"/>
 <result pre="the development of ARDS. Implications of Covid-19 in Obese Patients" exact="Obesity" post="is a common condition, affecting up to 30% of"/>
 <result pre="the location of the adipose tissue. However, all profiles of" exact="obesity" post="are not equivalent in terms of their consequences. Indeed,"/>
 <result pre="equivalent in terms of their consequences. Indeed, abdominal (or visceral)" exact="obesity" post="(estimated by the waist circumference or waist-to-hip ratio), in"/>
 <result pre="fat predominates, is more associated with metabolic disorders such as" exact="type 2" post="diabetes or hypertension, compared to â€œmetabolically healthyâ€� obesity, in"/>
 <result pre="is more associated with metabolic disorders such as type 2" exact="diabetes" post="or hypertension, compared to â€œmetabolically healthyâ€� obesity, in which"/>
 <result pre="subcutaneous fat predominates. Early observations in the SARS-CoV-2 epidemics suggested" exact="obesity" post="to be a risk factor to COVD-19, or at"/>
 <result pre="to COVD-19, or at least to severe forms of the" exact="disease" post="(50). In our retrospective cohort, we observed more than"/>
 <result pre="retrospective cohort, we observed more than 60% of patients with" exact="overweight" post="or obesity (n = 155) (Figure 1). In a"/>
 <result pre="we observed more than 60% of patients with overweight or" exact="obesity" post="(n = 155) (Figure 1). In a retrospective cohort,"/>
 <result pre="(female and male) admitted to Grenoble University Hospital for severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (retrospective cohort study)."/>
 <result pre="and male) admitted to Grenoble University Hospital for severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) infection (retrospective cohort study). Histogram"/>
 <result pre="male) admitted to Grenoble University Hospital for severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) infection (retrospective cohort study). Histogram illustrating"/>
 <result pre="University Hospital for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)" exact="infection" post="(retrospective cohort study). Histogram illustrating that a majority of"/>
 <result pre="of COVID patients, more precisely, 64% of COVID-19 patients were" exact="overweight" post="or obese (BMI &amp;gt; 25 kg/m2). The median BMI"/>
 <result pre="and males (M) was 26.30 and 27.08 kg/m2, respectively. Thus," exact="obesity" post="appears to be a risk factor for presenting a"/>
 <result pre="of COVID-19. It should be mentioned that once in ICU," exact="obesity" post="is known to confer a survival advantage, termed the"/>
 <result pre="or low BMI (55, 56), presumably due to their elevated" exact="muscle" post="mass, which represents a metabolic reserve in the hypermetabolic"/>
 <result pre="The scientific observations of the last two decades have placed" exact="obesity" post="in a complex pathological framework centered around the deregulation"/>
 <result pre="deregulation of the adipokine profile links various disorders associated with" exact="metabolic diseases," post="such as insulin-resistance, to inflammatory manifestations, as described in"/>
 <result pre="diseases, such as insulin-resistance, to inflammatory manifestations, as described in" exact="rheumatoid arthritis" post="(64). Ang1-7 takes an active role in regulating the"/>
 <result pre="such as insulin-resistance, to inflammatory manifestations, as described in rheumatoid" exact="arthritis" post="(64). Ang1-7 takes an active role in regulating the"/>
 <result pre="already arisen from these observations, particularly in the field of" exact="atherosclerosis" post="and non-alcoholic fatty liver disease, in which Ang1-7 seems"/>
 <result pre="from these observations, particularly in the field of atherosclerosis and" exact="non-alcoholic fatty liver" post="disease, in which Ang1-7 seems beneficial. In a concise"/>
 <result pre="these observations, particularly in the field of atherosclerosis and non-alcoholic" exact="fatty liver disease," post="in which Ang1-7 seems beneficial. In a concise article,"/>
 <result pre="observations, particularly in the field of atherosclerosis and non-alcoholic fatty" exact="liver disease," post="in which Ang1-7 seems beneficial. In a concise article,"/>
 <result pre="could impair the energetic functions of these pathways during SARS-CoV" exact="infections" post="(65). We suggest that the tampering with such pathways"/>
 <result pre="to abnormalities in the inflammatory response observed in severe CoV" exact="infections" post="through their influence on immune regulation and cytokine production."/>
 <result pre="immune regulation and cytokine production. Meta-Inflammation in Obese Patients and" exact="Viral" post="Response Adipocyte dysfunction in visceral fat is correlated to"/>
 <result pre="or an early factor in metabolic disorders associated with severe" exact="obesity" post="(63). This meta-inflammation is mostly driven by the leptin-activated"/>
 <result pre="inhibit NFkB activation, but as mentioned above, depending on the" exact="obesity" post="severity and profile, the effects of adiponectin can easily"/>
 <result pre="activation and neutrophil production, obese patients exhibit abnormal responses to" exact="viral infection." post="As summarized by Honce et al., during influenza infections,"/>
 <result pre="well as a strong cytokine production, notably IL-6, IP-10, and" exact="type 3" post="INF, which are elevated in severe COVID-19. Interestingly, patients"/>
 <result pre="patients with visceral fat accumulation also tend to have a" exact="lower" post="TLR3 expression in adipocytes, muscle cells, and adipose tissue-resident"/>
 <result pre="also tend to have a lower TLR3 expression in adipocytes," exact="muscle" post="cells, and adipose tissue-resident macrophages, as well as a"/>
 <result pre="cells, and adipose tissue-resident macrophages, as well as a concomitant" exact="lower" post="production of cytokines following exposure to viral PAMPS (71â€&quot;73)."/>
 <result pre="as a concomitant lower production of cytokines following exposure to" exact="viral" post="PAMPS (71â€&quot;73). This suggests that their baseline profile resembles"/>
 <result pre="efficient, but the overall inflammation is higher than in other" exact="viral" post="infections. Finally, both obesity and metabolic disorders are associated"/>
 <result pre="inflammation is higher than in other viral infections. Finally, both" exact="obesity" post="and metabolic disorders are associated with vascular dysfunction. At"/>
 <result pre="infections. Finally, both obesity and metabolic disorders are associated with" exact="vascular" post="dysfunction. At the acute phase of lung infection, this"/>
 <result pre="and metabolic disorders are associated with vascular dysfunction. At the" exact="acute" post="phase of lung infection, this could result in microcirculatory"/>
 <result pre="and increased lung edema. Discussion Patients with visceral fat accumulation," exact="type 2" post="diabetes (74), and hypertension are not the only subjects"/>
 <result pre="lung edema. Discussion Patients with visceral fat accumulation, type 2" exact="diabetes" post="(74), and hypertension are not the only subjects at"/>
 <result pre="Patients with visceral fat accumulation, type 2 diabetes (74), and" exact="hypertension" post="are not the only subjects at a higher risk"/>
 <result pre="severe SARS-CoV-2 infection. When considering metabolic disorders separately, diabetes, non-alcoholic" exact="liver disease," post="and obstructive sleep disorders have been recently reported as"/>
 <result pre="considering metabolic disorders separately, diabetes, non-alcoholic liver disease, and obstructive" exact="sleep disorders" post="have been recently reported as risk factors for a"/>
 <result pre="that the metabolic dysfunction associated with these disorders more than" exact="obesity" post="alone might be involved in the severity of the"/>
 <result pre="obesity alone might be involved in the severity of the" exact="disease" post="in these patients. When comparing the effects of Ang1-7"/>
 <result pre="with metabolic disorders, primarily visceral fat accumulation, have a constitutional" exact="lower" post="titer of Ang1-7, as suggested by some observations (77),"/>
 <result pre="improve fitness upon SARS-CoV infection. Figure 2 Impact of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) on pathways promoting acute"/>
 <result pre="fitness upon SARS-CoV infection. Figure 2 Impact of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) on pathways promoting acute respiratory"/>
 <result pre="upon SARS-CoV infection. Figure 2 Impact of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) on pathways promoting acute respiratory distress"/>
 <result pre="severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on pathways promoting" exact="acute" post="respiratory distress syndrome (ARDS). By inactivating the angiotensin conversion"/>
 <result pre="acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on pathways promoting acute" exact="respiratory" post="distress syndrome (ARDS). By inactivating the angiotensin conversion enzyme"/>
 <result pre="syndrome coronavirus 2 (SARS-CoV-2) on pathways promoting acute respiratory distress" exact="syndrome" post="(ARDS). By inactivating the angiotensin conversion enzyme 2 (ACE2),"/>
 <result pre="SARS-CoV-2 leads to an accumulation of angiotensin 2 and a" exact="lower" post="dosage of angiotensin 1-7, respectively resulting in the higher"/>
 <result pre="of angiotensin 1-7, respectively resulting in the higher promotion and" exact="lower" post="inhibition of pro-inflammatory signals. ACE2 deficiency has already been"/>
 <result pre="the higher promotion and lower inhibition of pro-inflammatory signals. ACE2" exact="deficiency" post="has already been explored by some research teams to"/>
 <result pre="hypertension, among others. Their studies highlighted the association between ACE2" exact="deficiency" post="and higher titers of pro-inflammatory cytokines in obese mice,"/>
 <result pre="cytokines in obese mice, as well as in mice with" exact="glucose intolerance" post="(78), which is closely correlated with meta-inflammation (79). Other"/>
 <result pre="is closely correlated with meta-inflammation (79). Other studies correlate ACE2" exact="deficiency" post="with epicardial inflammation (80). This suggests that the Ang1-7/MAS"/>
 <result pre="stress in obese mice, with a protective effect against diabetic" exact="cardiomyopathy" post="(82). Ang1-7 is already in the spotlight of scientific"/>
 <result pre="its beneficial effects in preventing the development of metabolic disorders" exact="and obesity" post="(83). We believe that our literature review highlights the"/>
 <result pre="beneficial effects in preventing the development of metabolic disorders and" exact="obesity" post="(83). We believe that our literature review highlights the"/>
 <result pre="highlights the beneficial effects of Ang1-7 on meta-inflammation in preexisting" exact="obesity" post="and its potential involvement in inflammatory response and viral"/>
 <result pre="preexisting obesity and its potential involvement in inflammatory response and" exact="viral" post="clearance, notably against SARS-CoV-2. Modulation of the renin-angiotensin system"/>
 <result pre="explain the severity of COVID-19. A recent study found a" exact="lower" post="mortality and intubation risk during COVID-19 among elderly patients"/>
 <result pre="supplementation could be a therapeutic option to diminish the low-grade" exact="systemic" post="inflammation due to adipocyte dysfunction and attenuate the severity"/>
 <result pre="in endothelia, with safe outcomes (87). Conclusion COVID-19 is a" exact="viral" post="disease with remarkable characteristics given its high severity in"/>
 <result pre="endothelia, with safe outcomes (87). Conclusion COVID-19 is a viral" exact="disease" post="with remarkable characteristics given its high severity in obese"/>
 <result pre="more than being just an incentive to accelerate research on" exact="viral infection," post="COVID-19 also presents an opportunity to respond to questions"/>
 <result pre="infection, angiotensin metabolism, global inflammation, and metabolic disorders such as" exact="type 2" post="diabetes and obesity should provide us with a better"/>
 <result pre="metabolism, global inflammation, and metabolic disorders such as type 2" exact="diabetes" post="and obesity should provide us with a better insight"/>
 <result pre="global inflammation, and metabolic disorders such as type 2 diabetes" exact="and obesity" post="should provide us with a better insight into the"/>
 <result pre="inflammation, and metabolic disorders such as type 2 diabetes and" exact="obesity" post="should provide us with a better insight into the"/>
 <result pre="which these conditions and physiological states interact outside of an" exact="acute" post="aggression. Data Availability Statement The raw data supporting the"/>
 <result pre="will be made available by the authors within respect of" exact="General" post="Data Protection Regulation, without undue reservation. Ethics Statement The"/>
 <result pre="The authors declare that the research was conducted in the" exact="absence of" post="any commercial or financial relationships that could be construed"/>
 <result pre="Foundation of Grenoble Alpes University, Grenoble, France. References References 1.ChengVCCLauSKPWooPCYYuenKY." exact="Severe" post="acute respiratory syndrome coronavirus as an agent of emerging"/>
 <result pre="of Grenoble Alpes University, Grenoble, France. References References 1.ChengVCCLauSKPWooPCYYuenKY. Severe" exact="acute" post="respiratory syndrome coronavirus as an agent of emerging and"/>
 <result pre="Grenoble Alpes University, Grenoble, France. References References 1.ChengVCCLauSKPWooPCYYuenKY. Severe acute" exact="respiratory" post="syndrome coronavirus as an agent of emerging and reemerging"/>
 <result pre="Alpes University, Grenoble, France. References References 1.ChengVCCLauSKPWooPCYYuenKY. Severe acute respiratory" exact="syndrome" post="coronavirus as an agent of emerging and reemerging infection."/>
 <result pre="infection. Clin Microbiol Rev. (2007) 20:660â€&quot;94. 10.1128/CMR.00023-0717934078 2.collab: WHOSARS (Severe" exact="Acute" post="Respiratory Syndrome). Available online at: https://www.who.int/ith/diseases/sars/en/ 3.PeirisJSMLaiSTPoonLLMGuanYYamLYCLimWet al.. Coronavirus"/>
 <result pre="Clin Microbiol Rev. (2007) 20:660â€&quot;94. 10.1128/CMR.00023-0717934078 2.collab: WHOSARS (Severe Acute" exact="Respiratory" post="Syndrome). Available online at: https://www.who.int/ith/diseases/sars/en/ 3.PeirisJSMLaiSTPoonLLMGuanYYamLYCLimWet al.. Coronavirus as"/>
 <result pre="https://www.who.int/ith/diseases/sars/en/ 3.PeirisJSMLaiSTPoonLLMGuanYYamLYCLimWet al.. Coronavirus as a possible cause of severe" exact="acute" post="respiratory syndrome. Lancet. (2003) 361:1319â€&quot;25. 10.1016/S0140-6736(03)13077-212711465 4.HuiDSWongPWangC. SARS: clinical"/>
 <result pre="3.PeirisJSMLaiSTPoonLLMGuanYYamLYCLimWet al.. Coronavirus as a possible cause of severe acute" exact="respiratory" post="syndrome. Lancet. (2003) 361:1319â€&quot;25. 10.1016/S0140-6736(03)13077-212711465 4.HuiDSWongPWangC. SARS: clinical features"/>
 <result pre="and transmission. Virol J. (2015) 12:222. 10.1186/s12985-015-0439-526695637 6.collab: WHOMiddle East" exact="Respiratory" post="Syndrome Coronavirus (MERS-CoV). (2020). Available online at: https://www.who.int/emergencies/mers-cov/en/ (accessed"/>
 <result pre="transmission. Virol J. (2015) 12:222. 10.1186/s12985-015-0439-526695637 6.collab: WHOMiddle East Respiratory" exact="Syndrome" post="Coronavirus (MERS-CoV). (2020). Available online at: https://www.who.int/emergencies/mers-cov/en/ (accessed May"/>
 <result pre="15, 2020). 7.ZhuNZhangDWangWLiXYangBSongJet al.. A novel coronavirus from patients with" exact="pneumonia" post="in China, 2019. N Engl J Med. (2020) 382:727â€&quot;33."/>
 <result pre="(2020) 395:497â€&quot;506. 10.1016/S0140-6736(20)30183-531986264 9.PhuaJWengLLingLEgiMLimC-MDivatiaJVet al.. Intensive care management of coronavirus" exact="disease" post="2019 (COVID-19): challenges and recommendations. Lancet Respir Med. (2020)"/>
 <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive study. Lancet. (2020) 395:507â€&quot;13."/>
 <result pre="descriptive study. Lancet. (2020) 395:507â€&quot;13. 10.1016/S0140-6736(20)30211-732007143 11.CalfeeCSDelucchiKParsonsPEThompsonBTWareLBMatthayMAet al.. Subphenotypes in" exact="acute" post="respiratory distress syndrome: latent class analysis of data from"/>
 <result pre="study. Lancet. (2020) 395:507â€&quot;13. 10.1016/S0140-6736(20)30211-732007143 11.CalfeeCSDelucchiKParsonsPEThompsonBTWareLBMatthayMAet al.. Subphenotypes in acute" exact="respiratory" post="distress syndrome: latent class analysis of data from two"/>
 <result pre="trials. Lancet Respir Med. (2014) 2:611â€&quot;20. 10.1016/S2213-2600(14)70097-924853585 12.ChannappanavarRFehrARVijayRMackMZhaoJMeyerholzDKet al.. Dysregulated" exact="type I" post="interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in"/>
 <result pre="Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal" exact="pneumonia" post="in SARS-CoV-infected mice. Cell Host Microbe. (2016) 19:181â€&quot;93. 10.1016/j.chom.2016.01.00726867177"/>
 <result pre="novel coronavirus: implication for development of RBD protein as a" exact="viral" post="attachment inhibitor and vaccine. Cell Mol Immunol. (2020) 17:613â€&quot;20."/>
 <result pre="23.MoralesMGAbrigoJMenesesCCisternasFSimonFCabello-VerrugioC. Expression of the Mas receptor is upregulated in skeletal" exact="muscle" post="wasting. Histochem Cell Biol. (2015) 143:131â€&quot;41. 10.1007/s00418-014-1275-125208653 24.SinghYGuptaGSharmaRMattaYMishraAPintoTdeJAet al.."/>
 <result pre="24.SinghYGuptaGSharmaRMattaYMishraAPintoTdeJAet al.. Embarking effect of ACE2-angiotensin 1-7/Mas receptor axis in" exact="benign" post="prostate hyperplasia. Crit Rev Eukaryot Gene Expr. (2018) 28:115â€&quot;24."/>
 <result pre="Rev Eukaryot Gene Expr. (2018) 28:115â€&quot;24. 10.1615/CritRevEukaryotGeneExpr.201802136430055537 25.ZhangCJiangZShaoCClinical characteristics of" exact="allergic bronchopulmonary aspergillosis." post="Clin Respir J. (2020) 131:1108â€&quot;9. 10.1111/crj.13147 26.SobrinoAVallejoSNovellaSLÃ¡zaro-FrancoMMompeÃ³nABueno-BetÃ­Cet al.. Mas"/>
 <result pre="vaccine. Paediatr Respir Rev. (2004) 5:300â€&quot;3. 10.1016/j.prrv.2004.07.00515531254 31.LauYLPeirisJSMPathogenesis of severe" exact="acute" post="respiratory syndrome. Curr Opin Immunol. (2005) 17:404â€&quot;10. 10.1016/j.coi.2005.05.00915950449 32.LawHKWCheungCYNgHYSiaSFChanYOLukWet"/>
 <result pre="Paediatr Respir Rev. (2004) 5:300â€&quot;3. 10.1016/j.prrv.2004.07.00515531254 31.LauYLPeirisJSMPathogenesis of severe acute" exact="respiratory" post="syndrome. Curr Opin Immunol. (2005) 17:404â€&quot;10. 10.1016/j.coi.2005.05.00915950449 32.LawHKWCheungCYNgHYSiaSFChanYOLukWet al.."/>
 <result pre="TRIF contributes to a protective innate immune response to severe" exact="acute" post="respiratory syndrome coronavirus infection. mBio. (2015) 6:15. 10.1128/mBio.00638-1526015500 34.IvashkivLBDonlinLT."/>
 <result pre="contributes to a protective innate immune response to severe acute" exact="respiratory" post="syndrome coronavirus infection. mBio. (2015) 6:15. 10.1128/mBio.00638-1526015500 34.IvashkivLBDonlinLT. Regulation"/>
 <result pre="to a protective innate immune response to severe acute respiratory" exact="syndrome" post="coronavirus infection. mBio. (2015) 6:15. 10.1128/mBio.00638-1526015500 34.IvashkivLBDonlinLT. Regulation of"/>
 <result pre="syndrome coronavirus infection. mBio. (2015) 6:15. 10.1128/mBio.00638-1526015500 34.IvashkivLBDonlinLT. Regulation of" exact="type I" post="interferon responses. Nat Rev Immunol. (2014) 14:36â€&quot;49. 10.1038/nri358124362405 35.KindlerEThielVWeberF."/>
 <result pre="(2008) 6:e226. 10.1371/journal.pbio.006022618798692 38.MenacheryVDYountBLJossetLGralinskiLEScobeyTAgnihothramSet al.. Attenuation and restoration of severe" exact="acute" post="respiratory syndrome coronavirus mutant lacking 2â€²-O-methyltransferase activity. J Virol."/>
 <result pre="6:e226. 10.1371/journal.pbio.006022618798692 38.MenacheryVDYountBLJossetLGralinskiLEScobeyTAgnihothramSet al.. Attenuation and restoration of severe acute" exact="respiratory" post="syndrome coronavirus mutant lacking 2â€²-O-methyltransferase activity. J Virol. (2014)"/>
 <result pre="10.1371/journal.pbio.006022618798692 38.MenacheryVDYountBLJossetLGralinskiLEScobeyTAgnihothramSet al.. Attenuation and restoration of severe acute respiratory" exact="syndrome" post="coronavirus mutant lacking 2â€²-O-methyltransferase activity. J Virol. (2014) 88:4251â€&quot;64."/>
 <result pre="J Mol Sci. (2016) 17:678. 10.3390/ijms1705067827164085 40.HuYLiWGaoTCuiYJinYLiPet al.. The severe" exact="acute" post="respiratory syndrome coronavirus nucleocapsid inhibits type I interferon production"/>
 <result pre="Mol Sci. (2016) 17:678. 10.3390/ijms1705067827164085 40.HuYLiWGaoTCuiYJinYLiPet al.. The severe acute" exact="respiratory" post="syndrome coronavirus nucleocapsid inhibits type I interferon production by"/>
 <result pre="Sci. (2016) 17:678. 10.3390/ijms1705067827164085 40.HuYLiWGaoTCuiYJinYLiPet al.. The severe acute respiratory" exact="syndrome" post="coronavirus nucleocapsid inhibits type I interferon production by interfering"/>
 <result pre="40.HuYLiWGaoTCuiYJinYLiPet al.. The severe acute respiratory syndrome coronavirus nucleocapsid inhibits" exact="type I" post="interferon production by interfering with TRIM25-mediated RIG-I ubiquitination. J"/>
 <result pre="ubiquitination. J Virol. (2017) 91:16. 10.1128/JVI.02143-1628148787 41.Al-QahtaniAALyroniKAznaourovaMTseliouMAl-AnaziMRAl-AhdalMNet al.. Middle east" exact="respiratory" post="syndrome corona virus spike glycoprotein suppresses macrophage responses via"/>
 <result pre="J Virol. (2017) 91:16. 10.1128/JVI.02143-1628148787 41.Al-QahtaniAALyroniKAznaourovaMTseliouMAl-AnaziMRAl-AhdalMNet al.. Middle east respiratory" exact="syndrome" post="corona virus spike glycoprotein suppresses macrophage responses via DPP4-mediated"/>
 <result pre="SARS coronavirus nsp1 protein induces template-dependent endonucleolytic cleavage of mRNAs:" exact="viral" post="mRNAs are resistant to nsp1-induced RNA cleavage. PLoS Pathog."/>
 <result pre="cleavage. PLoS Pathog. (2011) 7:2433. 10.1371/journal.ppat.100243322174690 43.LokugamageKGNarayananKNakagawaKTerasakiKRamirezSITsengC-TKet al.. Middle east" exact="respiratory" post="syndrome coronavirus nsp1 inhibits host gene expression by selectively"/>
 <result pre="PLoS Pathog. (2011) 7:2433. 10.1371/journal.ppat.100243322174690 43.LokugamageKGNarayananKNakagawaKTerasakiKRamirezSITsengC-TKet al.. Middle east respiratory" exact="syndrome" post="coronavirus nsp1 inhibits host gene expression by selectively targeting"/>
 <result pre="mRNAs of cytoplasmic origin. J Virol. (2015) 89:10970â€&quot;81. 10.1128/JVI.01352-1526311885 44.FriemanMYountBHeiseMKopecky-BrombergSAPalesePBaricRS." exact="Severe" post="acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by"/>
 <result pre="of cytoplasmic origin. J Virol. (2015) 89:10970â€&quot;81. 10.1128/JVI.01352-1526311885 44.FriemanMYountBHeiseMKopecky-BrombergSAPalesePBaricRS. Severe" exact="acute" post="respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering"/>
 <result pre="cytoplasmic origin. J Virol. (2015) 89:10970â€&quot;81. 10.1128/JVI.01352-1526311885 44.FriemanMYountBHeiseMKopecky-BrombergSAPalesePBaricRS. Severe acute" exact="respiratory" post="syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear"/>
 <result pre="origin. J Virol. (2015) 89:10970â€&quot;81. 10.1128/JVI.01352-1526311885 44.FriemanMYountBHeiseMKopecky-BrombergSAPalesePBaricRS. Severe acute respiratory" exact="syndrome" post="coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import"/>
 <result pre="al.. Plasma IP-10 and MCP-3 levels are highly associated with" exact="disease" post="severity and predict the progression of COVID-19. J Allergy"/>
 <result pre="Clin Immunol. (2020) 146:119â€&quot;27. 10.1016/j.jaci.2020.04.02732360286 46.FungS-YYuenK-SYeZ-WChanC-PJinD-Y. A tug-of-war between severe" exact="acute" post="respiratory syndrome coronavirus 2 and host antiviral defence: lessons"/>
 <result pre="Immunol. (2020) 146:119â€&quot;27. 10.1016/j.jaci.2020.04.02732360286 46.FungS-YYuenK-SYeZ-WChanC-PJinD-Y. A tug-of-war between severe acute" exact="respiratory" post="syndrome coronavirus 2 and host antiviral defence: lessons from"/>
 <result pre="(2020) 146:119â€&quot;27. 10.1016/j.jaci.2020.04.02732360286 46.FungS-YYuenK-SYeZ-WChanC-PJinD-Y. A tug-of-war between severe acute respiratory" exact="syndrome" post="coronavirus 2 and host antiviral defence: lessons from other"/>
 <result pre="47.McGonagleDSharifKO'ReganABridgewoodC. The role of cytokines including interleukin-6 in COVID-19 induced" exact="pneumonia" post="and macrophage activation syndrome-like disease. Autoimmun Rev. (2020) 19:102537."/>
 <result pre="adaptive immunity, and its potential involvement in COVID-19-related thrombotic and" exact="vascular" post="mechanisms. Autoimmun Rev. (2020) 19:102572. 10.1016/j.autrev.2020.10257232376393 50.LiQGuanXWuPWangXZhouLTongYet al.. Early"/>
 <result pre="J Med. (2020) 382:1199â€&quot;207. 10.1056/NEJMoa200131631995857 51.SimonnetAChetbounMPoissyJRaverdyVNouletteJDuhamelAet al.. High prevalence of" exact="obesity" post="in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive"/>
 <result pre="382:1199â€&quot;207. 10.1056/NEJMoa200131631995857 51.SimonnetAChetbounMPoissyJRaverdyVNouletteJDuhamelAet al.. High prevalence of obesity in severe" exact="acute" post="respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity.28:1195â€&quot;9."/>
 <result pre="10.1056/NEJMoa200131631995857 51.SimonnetAChetbounMPoissyJRaverdyVNouletteJDuhamelAet al.. High prevalence of obesity in severe acute" exact="respiratory" post="syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity.28:1195â€&quot;9. 10.1002/oby.2283132271993"/>
 <result pre="51.SimonnetAChetbounMPoissyJRaverdyVNouletteJDuhamelAet al.. High prevalence of obesity in severe acute respiratory" exact="syndrome" post="coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity.28:1195â€&quot;9. 10.1002/oby.2283132271993 52.CaussyCPattouFWalletFSimonCChalopinSTelliamCet"/>
 <result pre="requiring invasive mechanical ventilation. Obesity.28:1195â€&quot;9. 10.1002/oby.2283132271993 52.CaussyCPattouFWalletFSimonCChalopinSTelliamCet al.. Prevalence of" exact="obesity" post="among adult inpatients with COVID-19 in France. Lancet Diabetes"/>
 <result pre="mechanical ventilation. Obesity.28:1195â€&quot;9. 10.1002/oby.2283132271993 52.CaussyCPattouFWalletFSimonCChalopinSTelliamCet al.. Prevalence of obesity among" exact="adult" post="inpatients with COVID-19 in France. Lancet Diabetes Endocrinol. (2020)"/>
 <result pre="of obesity among adult inpatients with COVID-19 in France. Lancet" exact="Diabetes" post="Endocrinol. (2020) 8:562â€&quot;4. 10.1016/S2213-8587(20)30160-132437642 53.DietzWSantos-BurgoaC. Obesity and its implications"/>
 <result pre="COVID-19 in France. Lancet Diabetes Endocrinol. (2020) 8:562â€&quot;4. 10.1016/S2213-8587(20)30160-132437642 53.DietzWSantos-BurgoaC." exact="Obesity" post="and its implications for COVID-19 mortality. Obesity. (2020) 28:1005."/>
 <result pre="cohort study. Am J Clin Nutr. (2014) 100:859â€&quot;66. 10.3945/ajcn.114.08818725080456 55.NieWZhangYJeeSHJungKJLiBXiuQ." exact="Obesity" post="survival paradox in pneumonia: a meta-analysis. BMC Med. (2014)"/>
 <result pre="meta-analysis. BMC Med. (2014) 12:61. 10.1186/1741-7015-12-6124722122 56.ZhiGXinWYingWGuohongXShuyingL. â€œObesity paradoxâ€� in" exact="acute" post="respiratory distress syndrome: asystematic review and meta-analysis. PLoS ONE."/>
 <result pre="BMC Med. (2014) 12:61. 10.1186/1741-7015-12-6124722122 56.ZhiGXinWYingWGuohongXShuyingL. â€œObesity paradoxâ€� in acute" exact="respiratory" post="distress syndrome: asystematic review and meta-analysis. PLoS ONE. (2016)"/>
 <result pre="function. Compr Physiol. (2018) 8:1031â€&quot;63. 10.1002/cphy.c17004629978896 61.FranciscoVRuiz-FernÃ¡ndezCPinoJMeraAGonzÃ¡lez-GayMAGÃ³mezRet al.. Adipokines: linking" exact="metabolic syndrome," post="the immune system, and arthritic diseases. Biochem Pharmacol. (2019)"/>
 <result pre="61.FranciscoVRuiz-FernÃ¡ndezCPinoJMeraAGonzÃ¡lez-GayMAGÃ³mezRet al.. Adipokines: linking metabolic syndrome, the immune system, and" exact="arthritic" post="diseases. Biochem Pharmacol. (2019) 165:196â€&quot;206. 10.1016/j.bcp.2019.03.03030910694 62.TrayhurnPAlomarSY. Oxygen deprivation"/>
 <result pre="165:196â€&quot;206. 10.1016/j.bcp.2019.03.03030910694 62.TrayhurnPAlomarSY. Oxygen deprivation and the cellular response to" exact="hypoxia" post="in adipocytesâ€&quot;perspectives on white and brown adipose tissues in"/>
 <result pre="66.DikmenKBostanciHGobutHYavuzAAlperMKeremM. Recombinant adiponectin inhibits inflammation processes via NF-kB pathway in" exact="acute" post="pancreatitis. Bratisl Lek Listy. (2018) 119:619â€&quot;24. 10.4149/BLL_2018_11030345768 67.ClaycombeKKingLEFrakerPJ. A"/>
 <result pre="neutrophils. J Immunol. (2005) 174:8090â€&quot;6. 10.4049/jimmunol.174.12.809015944317 69.ShahTJLeikCEWalshSW. Neutrophil infiltration and" exact="systemic" post="vascular inflammation in obese women. Reprod Sci. (2010) 17:116â€&quot;24."/>
 <result pre="J Immunol. (2005) 174:8090â€&quot;6. 10.4049/jimmunol.174.12.809015944317 69.ShahTJLeikCEWalshSW. Neutrophil infiltration and systemic" exact="vascular" post="inflammation in obese women. Reprod Sci. (2010) 17:116â€&quot;24. 10.1177/193371910934825219820230"/>
 <result pre="obese women. Reprod Sci. (2010) 17:116â€&quot;24. 10.1177/193371910934825219820230 70.HonceRSchultz-CherryS. Impact of" exact="obesity" post="on influenza A virus pathogenesis, immune response, and evolution."/>
 <result pre="activation lead to decreased MnSOD expression and insulin resistance in" exact="muscle" post="cells of obese people. Cell Death Dis. (2014) 5:e1136."/>
 <result pre="Biochem. (2018) 51:1051â€&quot;68. 10.1159/00049548730476912 73.Teran-CabanillasEMontalvo-CorralMCaire-JuveraGMoya-CamarenaSYHernÃ¡ndezJDecreased interferon-Î± and interferon-Î² production in" exact="obesity" post="and expression of suppressor of cytokine signaling. Nutrition. (2013)"/>
 <result pre="a risk factor for the progression and prognosis of COVID-19." exact="Diabetes" post="Metab Res Rev. (2020) 29:207â€&quot;12. 10.1002/dmrr.3319 75.GaoFZhengKIWangX-BYanH-DSunQ-FPanK-Het al.Metabolic associated"/>
 <result pre="Diabetes Metab Res Rev. (2020) 29:207â€&quot;12. 10.1002/dmrr.3319 75.GaoFZhengKIWangX-BYanH-DSunQ-FPanK-Het al.Metabolic associated" exact="fatty liver disease" post="increases COVID-19 disease severity in non-diabetic patients. J Gastroenterol"/>
 <result pre="Metab Res Rev. (2020) 29:207â€&quot;12. 10.1002/dmrr.3319 75.GaoFZhengKIWangX-BYanH-DSunQ-FPanK-Het al.Metabolic associated fatty" exact="liver disease" post="increases COVID-19 disease severity in non-diabetic patients. J Gastroenterol"/>
 <result pre="Res Rev. (2020) 29:207â€&quot;12. 10.1002/dmrr.3319 75.GaoFZhengKIWangX-BYanH-DSunQ-FPanK-Het al.Metabolic associated fatty liver" exact="disease" post="increases COVID-19 disease severity in non-diabetic patients. J Gastroenterol"/>
 <result pre="29:207â€&quot;12. 10.1002/dmrr.3319 75.GaoFZhengKIWangX-BYanH-DSunQ-FPanK-Het al.Metabolic associated fatty liver disease increases COVID-19" exact="disease" post="severity in non-diabetic patients. J Gastroenterol Hepatol. (2020). 10.1111/jgh.15112."/>
 <result pre="Gastroenterol Hepatol. (2020). 10.1111/jgh.15112. [Epub ahead of print]. 76.PazarliACEkizTIlikF. Coronavirus" exact="disease" post="2019 and obstructive sleep apnea syndrome. Sleep Breath. (2020)"/>
 <result pre="10.1111/jgh.15112. [Epub ahead of print]. 76.PazarliACEkizTIlikF. Coronavirus disease 2019 and" exact="obstructive sleep apnea" post="syndrome. Sleep Breath. (2020) 1. 10.1007/s11325-020-02087-0. [Epub ahead of"/>
 <result pre="[Epub ahead of print]. 76.PazarliACEkizTIlikF. Coronavirus disease 2019 and obstructive" exact="sleep apnea" post="syndrome. Sleep Breath. (2020) 1. 10.1007/s11325-020-02087-0. [Epub ahead of"/>
 <result pre="metabolism of high-fat feed mice. Peptides. (2014) 55:158â€&quot;65. 10.1016/j.peptides.2014.03.00624642355 78.ThatcherSEGupteMHatchNCassisLA." exact="Deficiency of" post="ACE2 in bone-marrow-derived cells increases expression of TNF-Î± in"/>
 <result pre="increases expression of TNF-Î± in adipose stromal cells and augments" exact="glucose intolerance" post="in obese C57BL/6 mice. Int J Hypertens. (2012) 2012:762094."/>
 <result pre="insulin resistance. J Clin Invest. (2006) 116:3015â€&quot;25. 10.1172/JCI2889817053832 80.PatelVBMoriJMcLeanBABasuRDasSKRamprasathTet al.ACE2" exact="deficiency" post="worsens epicardial adipose tissue inflammation and cardiac dysfunction in"/>
 <result pre="obesity. Diabetes. (2016) 65:85â€&quot;95. 10.2337/db15-039926224885 81.SantosSHSAndradeJMOFernandesLRSinisterraRDMSousaFBFeltenbergerJDet al.. Oral Angiotensin-(1-7) prevented" exact="obesity" post="and hepatic inflammation by inhibition of resistin/TLR4/MAPK/NF-ÎºB in rats"/>
 <result pre="high-fat diet. Peptides. (2013) 46:47â€&quot;52. 10.1016/j.peptides.2013.05.01023714175 82.SukumaranVTsuchimochiHTatsumiEShiraiMPearsonJT. Azilsartan ameliorates diabetic" exact="cardiomyopathy" post="in young db/db mice through the modulation of ACE-2/ANG"/>
 <result pre="10.1016/j.bcp.2017.07.02228789938 83.SantosSHSAndradeJMO. Angiotensin 1-7: a peptide for preventing and treating" exact="metabolic syndrome." post="Peptides. (2014) 59:34â€&quot;41. 10.1016/j.peptides.2014.07.00225017239 84.SolaimanzadehI. Nifedipine and Amlodipine Are"/>
 <result pre="N Engl J Med. (2020) 382:1653â€&quot;9. 10.1056/NEJMsr200576032227760 87.SchinzariFTesauroMVenezianiAMoresNDi DanieleNCardilloC. Favorable" exact="vascular" post="actions of angiotensin-(1-7) in human obesity. Hypertension. (2018) 71:185â€&quot;91."/>
</results>
